A Multicentre, Open Label, Early Stopping Design, Proof Of Concept Study With Tasquinimod In Treating Patients With Advanced Or Metastatic Hepatocellular, Ovarian, Renal Cell And Gastric Carcinomas.
The clinical activity of tasquinimod will be evaluated independently in each individual
cohort of patients of the four different tumour types, namely Cohort H, Cohort O, Cohort R
and Cohort G respectively.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression free survival [PFS] rate, defined as the proportion of patients who have neither progressed nor died as measured by RECIST v1.1 (both Cohorts H and R)
Nathalie GERMANN, M.D.
France: Agence Nationale de Sécurité du Médicament et des produits de santé